NCT07721129Not yet recruitingPhase 4
TeleStroke-Guided Thrombolysis for Acute Ischemic Stroke in Oman
Thrombolysis for Acute Ischemic Stroke Facilitated by TeleStroke: Oman TeleStroke Initiative
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
The goal of this study is to establish and examine the efficacy of using a Telestroke network in Oman to facilitate using emergent thrombolysis for patients with acute ischemic stroke encountered in selected peripheral hospitals. It is proposed to establish a TeleStroke network involving two central hospitals in Muscat linked to three to five peripheral hospitals in Oman which currently have access to CT scans and basic infrastructure for management of AIS patients- but do not have a Neurology service. Selected staff from Internal Medicine/Emergency Medicine departments, Nursing, Technical service and support staffs will be trained in the process of assessment and management of AIS patients including the use of IV alteplase or tenecteplase. They will also be trained in timely access of a Neurologist on call at the central hospital(s) using a TeleStroke network. The Neurologist would conduct a Telestroke based clinical assessment of the AIS patient, review imaging and laboratory results in a timely manner and advice the medical team at the peripheral hospital regarding administration of IV alteplase/tenecteplase. The main purpose of such consultation would be to recognize eligible patients for administration of IV thrombolysis safely at the earliest opportunity within 4.5 hours, leading to increased rates of such thrombolysis with expected improved outcomes. Outcomes would be compared among 100 patients with AIS managed across these 5 hospitals prior to initiation of the practice of thrombolysis and at least 100 patients treated each with IV alteplase using TeleStroke Consultation with Neurologist. Demonstration of efficacy of TeleStroke based stroke thrombolysis would lead to effective implementation of this practice in Oman.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (estimated)
- First submitted
- 16 Jul 2025
- Start date
- 1 Aug 2026
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Oman Ministry of Health
- Diseases
- Stroke
- NCT number
- NCT07721129
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 200
- From 1 Aug 2026 to the primary completion date, 30 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Arterial puncture at non compressible site in previous 7 days
- History of previous intracranial hemorrhage.
- Recent head injury OR intracranial or intraspinal surgery in last 3 mo.
- Recent MI within previous 3 months (to exclude anterolateral infarct / STEMI)
Other illness
- CT brain shows showing evidence of intracranial hemorrhage
- Active ongoing internal bleeding.
- Seizure at onset with post ictal residual neurological deficit.
- Signs of mild stroke in isolation or rapidly improving symptoms.
- Recent GI or UT hemorrhage within the last 21 days.
Lab values
- Platelet count \<100 000/mm3.
- Current use of NOACs OR warfarin with INR \>1.7 OR Inj.Enoxaparin/Heparin in therapeutic dose
- Blood glucose concentration \<2.7mmol/L (\<50mg/dl).
- Relative contraindications: (may consider IV alteplase on individual evaluation).
Other
- CT brain showing acute or subacute infarct of size about \>1/3 Middle Cerebral Artery territory.
- Intracranial neoplasm, AV malformation, or aneurysm
- Persistent Elevated BP \>185/110 mm Hg despite treatment.
- Pregnancy.
Who the study is looking for
- Age \>18 years. Acute neurologic deficits due to cerebral ischemia/infarction. Clearly defined onset with duration from stroke onset of \<4.5 hours. Significant neurological deficit (usually NIHSS score of 4-25).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.